Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 262 participants.
Also called NCT05136664
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 262 participants
- Sponsor
- Registry
-
NCT05136664
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05136664. Randomized; single masking; primary purpose treatment. Start 2022-02-10 (actual); primary completion 2025-11-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
- Acronym
- Patiromer JADE
- Condition
- Hyperkalemia
- Condition
- Renal Insufficiency, Chronic
- Intervention (Drug)
- Patiromer Powder for Oral Suspension (Part A)
- Intervention (Drug)
- Placebo (Part B)
- Intervention (Drug)
- Patiromer Powder for Orals Suspension (Part B)
- Lead sponsor
- Vifor Fresenius Medical Care Renal Pharma
- Collaborator
- Tigermed Consulting Co., Ltd
Record details
- Record id
cardio:ct-nct05136664- Content hash
e7b5b2ccbf7a7bcbe6e24de3e29ac5409577e2747ae06f01c403891b728a74f1